Revenue from operations rose 35.4% YoY to Rs 3,676 crore in Q2FY27, against Rs 2,715 crore reported in the year-ago period.
The pharmaceutical company reported consolidated total income of Rs 3,770 crore for the quarter ended September 30, compared with Rs 2,860 crore in the corresponding quarter of the previous year.
The company reported a foreign exchange gain of Rs 24 crore during the quarter, compared with a gain of Rs 63 crore in the corresponding quarter of the previous year.
On a standalone basis, total income for the September quarter stood at Rs 3,735 crore, compared with Rs 2,806 crore in the year-ago period. PAT rose to Rs 1,140 crore from Rs 696 crore.
For the half year ended September 30, 2026, Divi’s Laboratories reported consolidated total income of Rs 6,907 crore, compared with Rs 5,389 crore in the corresponding period of the previous fiscal. PAT increased to Rs 2,029 crore from Rs 1,234 crore.The company reported a foreign exchange gain of Rs 17 crore during the first half, compared with a gain of Rs 102 crore in the year-ago period.
On a standalone basis, total income for the first half stood at Rs 6,765 crore, compared with Rs 5,282 crore in the corresponding period last year. PAT increased to Rs 2,031 crore from Rs 1,253 crore.
Ahead of the results announcement, Divi’s Laboratories shares settled Friday’s trading session at Rs 10,305 apiece on the BSE, rising 1.53% from the previous close of Rs 10,150.
During the session, the stock traded in the range of Rs 10,049.30 to Rs 10,305 on the BSE.
The company had a market capitalization of Rs 2,73,565.37 crore on the BSE.
Disclosure: This article has been written by Kumar Gaurav, who is not a Sebi-registered Research Analyst or an Investment Adviser. Gaurav and their ‘relative(s)’ (as defined under Section 2(77) of the Companies Act, 2013) do not hold any financial interest in the companies mentioned in this article as of the date of publication. The views/recommendations mentioned in this article, wherever applicable, are those of the respective Sebi-registered Research Analyst/brokerage and have been reproduced/reported with due attribution. They should not be construed as the views or recommendations of The Economic Times Digital or the journalist. Readers are advised to consider the original research report and make their investment decisions based on their own assessment. Brokerage disclaimers here
